Characterization of MPL-nanoliposomes with Her2/neu derived peptide GP2 as vaccine against breast cancer in BALB/c mice TUBO xenograft model
- سال انتشار: 1396
- محل انتشار: کنفرانس و کارگاه بین المللی نانوفناوری و نانو پزشکی NTNM 2017
- کد COI اختصاصی: NTNM01_042
- زبان مقاله: انگلیسی
- تعداد مشاهده: 696
نویسندگان
Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran; Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran; Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
چکیده
HER2/neu is an immunogenic protein eliciting both humoral and cellular immune responses in patients with HER2/neu-positive tumors. The goal of this study was to induce and enhance an effective cytotoxic T lymphocyte (CTL) response against peptide Gp2 derived from HER 2/neu oncogene and MPL adjuvant by employing the potential benefit of liposomes as a co-delivery vehicle. MPL have been shown to have potent adjuvant activity for a wide range of antigens. In this study, different groups of mice were subcutaneously vaccinated with five formulations containing DMPC/DMPG/Chol (30:4:6) with or without DOPE, MPL (25 µg per mouse) and peptide conjugated to - DSPE- mPEG2000- Maleimide lipid and also Hepes/sucrose buffer as control. Released amount of IFN-γ were determined by flow cytometric analysis, ELISpot kits, Intracellular cytokine assay and RT-PCR was used to identify IFN-γ and IL-4 producing cells. Consequently, mice immunized with lip-DOPE-MPL-GP2 formulation had the most released IFN-γ and the highest CTL responses followed by Lip-Gp2 and GP2 formulation groupکلیدواژه ها
HER2/neu; GP2 peptide; antigen-specific immunity; cytotoxic T lymphocyte; MPL;اطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.